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Abstract
Background: The optimal management of croup – a common respiratory illness in young children – is
well established. In particular, treatment with corticosteroids has been shown to significantly reduce the
rate and duration of intubation, hospitalization, and return to care for on-going croup symptoms.
Furthermore treatment with a single dose of corticosteroids does not appear to result in any significant
adverse outcomes, and yields overall cost-savings for both families and the health care system.
However, as has been shown with many other diseases, there is a significant gap between what we know
and what we do. The overall aim of this study is to identify, from a societal perspective, the costs and
associated benefits of three strategies for implementing a practice guideline that addresses the
management of croup.
Methods/designs: We propose to use a matched pair cluster trial in 24 Alberta hospitals randomized
into three intervention groups. We will use mixed methods to assess outcomes including linkage and
analysis of administrative databases obtained from Alberta Health and Wellness, retrospective medical
chart audit, and prospective telephone surveys of the parents of children diagnosed to have croup. The
intervention strategies to be compared will be mailing of printed educational materials (low intensity
intervention), mailing plus a combination of interactive educational meetings, educational outreach visits,
and reminders (intermediate intensity intervention), and a combination of mailing, interactive sessions,
outreach visits, reminders plus identification of local opinion leaders and establishment of local consensus
processes (high intensity intervention). The primary objective is to determine which of the three
intervention strategies are most effective at lowering the rate of hospital days per 1,000 disease episodes.
Secondary objectives are to determine which of the three dissemination strategies are most effective at
increasing the use of therapies of known benefit. An economic analysis will be conducted to determine
which of the three intervention strategies will most effectively reduce total societal costs including all
health care costs, costs borne by the family, and costs stemming from the strategies for disseminating
guidelines.
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Background
Introduction
Compared with biomedical research, few resources have
been devoted to translating knowledge into practice.
However health care researchers are increasingly aware of
the persistent and substantial gap between what we know
and what we do. One of the most common strategies
advocated for closing this gap is the development of prac-
tice guidelines. It is now widely accepted, however, that
simple dissemination whether by publication in medical
journals or direct mailings to physicians of guidelines,
does not result in a significant change in practice.
More than 40 systematic reviews have been published
which examine a range of different strategies for imple-
menting guidelines. An overview of this literature has
been published by the Cochrane Effective Practice and
Organisation of Care (EPOC) Group.[1,2] This review
concludes that many of the primary studies focusing on
implementation strategies have weak designs, methodo-
logical flaws, and that virtually none have included eco-
nomic evaluations. The authors call for randomized trials
with head-to-head, multi-arm comparisons of different
levels of interventions, that use an appropriate analysis,
based on clusters, and include a comprehensive cost-effec-
tive analysis.
We have designed a study that addresses each of the points
outlined by the EPOC Group's members. Furthermore we
believe – for several reasons – that practice guidelines
addressing the management of croup will provide a good
test case for analyzing our proposed intervention.
Croup is second only to asthma as a cause of respiratory
emergencies in young children, and accounts for 5% of all
emergent admissions in this population. In the last 15
years, as a result of the publication of a number of thera-
peutic trials and systematic reviews, the scientific basis for
croup treatment has been clarified. In particular, opti-
mally timed treatment with steroids substantially reduces
the frequency and duration of both hospitalization and
airway intubation. [3-5]
Published literature and pilot data collected for this pro-
posed trial show that many children with croup do not
receive optimal therapy, and that there is a substantial var-
iation in hospitalization rates.[6,7] Since hospitalization
likely accounts for most health care spending on this dis-
ease, improvement in prescribing practices and standard-
ization of indications for hospital admission could both
improve outcomes and substantially reduce health care
expenditures for children with croup.
Strategies for disseminating and implementing clinical practice 
guidelines
The "Gap"
On-going societal investment in basic and clinical
research is ultimately only meaningful if this acquired
knowledge is translated into better care for patients.
Unfortunately, in health care, there is a substantial gap
between what is known and what is actually done for
patients. Though this has been recognized for some time,
this gap has not disappeared. Some well-documented
examples include the use of photocoagulation for diabetic
retinopathy,[8] management of hypertension,[8] prophy-
laxis for patients at high risk for venous thrombosis and
pulmonary embolism,[8] and, most recently, thrombo-
lytic therapy for patients with myocardial infarction. [8-
10]
Approaches to knowledge translation
Many different broad approaches to knowledge transla-
tion have been advocated including development and dis-
semination of clinical practice guidelines, continuing
medical education, continuous quality improvement, and
more recently, computerized decision support sys-
tems.[11,12]
What constitutes a good practice guideline?
Guidelines are formally defined as "systematically devel-
oped statements to assist practitioners' and patients' deci-
sions about appropriate care for specified clinical
outcomes".[13] A number of organizations have devel-
oped policies and standards for how guidelines should be
developed and evaluated. [12-17] It is desirable for guide-
lines to be valid (i.e. if followed, guidelines should yield
the health care gains and costs predicted); reproducible
(i.e. if given the same evidence and methods, two commit-
tees should develop comparable guidelines); and reliable
(i.e. in the same clinical circumstances, clinicians should
interpret the guidelines in the same way).[9] Guidelines
are most likely to be valid if developed by national organ-
izations with representatives from all key disciplines, and
if formally linked to meta-analysis.[9]
Guideline development is expensive and often falls short
Development of guidelines can be very expensive, espe-
cially those developed by national agencies which can
range up to US $1 million.[17] Furthermore, there are
more than 20,000 guidelines registered in the U.S.
National Guideline Clearinghouse, and more than 2,000
guidelines on the Canadian Medical Association Web-
site.[18] Consequently the total amount of health
resource dollars now devoted to guideline development is
considerable. For example, the United Kingdom spends
an estimated 1.5% of the annual health budget on the
development of national guidelines.Implementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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A critical review of practice guidelines found that, of the
guidelines published in a selection of journals in the last
decade, none meet all methodological standards, and few
met more than 70% of standards.[19] The methodologi-
cal area in which guidelines needed the greatest improve-
ment was the identification, evaluation, and synthesis of
scientific evidence.
Dissemination alone doesn't work
It is now widely accepted that no matter how well-devel-
oped practice guidelines are, simple dissemination does
not result in a significant change in practice.[1,2] A
number of different strategies to implement guidelines
have been published. Cochrane Effective Practice And
Organisation Of Care Group http://www.abdn.ac.uk/
hsru/epoc/ has systematically reviewed the published lit-
erature, developed a taxonomy of interventions, and
developed methodological criteria for assessing the qual-
ity of the evaluation of these interventions.
Implementation strategies: what works and what doesn't work
Based on published reviews by the Cochrane EPOC
Group and others, we can broadly categorize the different
implementation strategies into three groups as showing
consistent, variable, or little or no effectiveness.[1,2]
Those interventions that consistently have shown effec-
tiveness include interactive educational meetings, educa-
tional outreach visits, reminders (either manual or
computerized), and multifaceted interventions (defined
as a minimum of two combined interventions). Interven-
tions that have shown a range of effectiveness include
audit and feedback, the use of local opinion leaders, local
consensus processes, and patient-mediated interventions.
Interventions that have consistently shown little or no
effect are didactic educational meetings (lecture-format)
and educational materials (distribution of recommenda-
tions for clinical care, including practice guidelines, audi-
ovisual materials, and electronic publications).
Management of children with croup
Clinical presentation and infectious etiology
Croup (acute laryngotracheo-bronchitis) is a common
respiratory tract illness in young children. Parainfluenza
virus is, by far, the most common cause of croup. Other
important causes include influenza, adeno, and respira-
tory syncytial viruses.[20,21] The illness is characterized
by a barking cough, hoarseness, inspiratory stridor, and
often severe respiratory distress that can occur suddenly in
the middle of the night. This can be frightening for par-
ents. The barking cough is distinct for croup. It and the
accompanying inspiratory stridor are easily recognizable
by clinicians and, once educated, by parents.
Epidemiology & burden of the disease
It most commonly affects children between the ages of 6
months to 3 years.[21] The disease peaks biannually, with
the largest peak between September and December and a
second smaller peak between January and March.[22]
Croup accounts for a significant proportion of paediatric
emergency department (ED) visits and hospitalizations.
The proportion of children evaluated as outpatients who
are hospitalized range from 1–6% of those seen in private
physician offices, to 7–31% of those evaluated in an
ED.[21,23-25] Hospitalizations of children with croup are
typically short, with the median duration being 48 hours.
The potential for respiratory failure and death is what
drives physicians to consider hospitalization. However,
endotracheal intubation is uncommon (0.4–1.4% of hos-
pitalized children), and death is exceptionally rare (0.5%
of intubated children).[26]
Indications for hospital admission
Few studies have examined which children are at risk for
respiratory failure. A retrospective cohort study of 527
hospitalized children suggested that the presence or
absence of persistent sternal and chest wall indrawing
may be an important clinical factor in determining
risk.[27] A small prospective study suggests that the insti-
tution of a clinical pathway for croup in an ED – using
explicit criteria for when it is safe to discharge children
home – can significantly reduce admission rates and
length of stay without any significant adverse events.[28]
Variability in hospitalization rates
Using the technique of small area analysis, To and Wen-
nberg have reported a five and 17-fold difference, respec-
tively, in the rate of hospitalization per capita among
communities. Wennberg noted that the rate for croup and
several other common pediatric problems, relative to
adult medical conditions, was significantly more varia-
ble.[6,7]
BaselineUtilisation data from Alberta
Utilizing provincial administrative data, we have estab-
lished health care utilization rates including the a)
number of disease episodes, b) number of physician visits
per disease episode, and c) number of hospital admis-
sions and hospitals days per disease episode, for children
with croup in Alberta for 6 years. Among the 107 Alberta
hospitals, we found up to an 18 fold range in hospital
admissions rates, ranging from16 to 287/1000 disease
episodes. In general, those hospitals that evaluated larger
numbers of children with croup had lower utilization
rates. For example, the six largest volume hospitals diag-
nosed a total of 86,711 cases, and averaged 21 hospital
admissions/1,000 disease episodes; and the 30 smallest
volume hospitals diagnosed 13,750 cases and averaged
116 hospital admissions/1,000 disease episodes.Implementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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Costs associated with hospitalization
Though there are no comprehensive studies examining
the health care costs of croup, one study suggests that the
total 'costs' for hospitalization were almost three times
that of the total costs for all ED visits.[23] In the case of
bronchiolitis – which likely has a similar costing structure
to croup – 62% of all health care expenditures for the dis-
ease are expended on the less than 1% of children who are
admitted to hospital.[29] Our baseline provincial data for
croup shows that the average number of MD visits per dis-
ease episode is only 1.15, and that 3.6% of children with
croup are hospitalised. Given the relative greater costs
associated with hospital admission versus MD visits, or
other costs such as medications, it is likely that hospital
admissions are the principal determinant of health expen-
ditures. Therefore a substantial reduction in hospitaliza-
tion rates should substantially reduce health care
expenditures for the disease.
Overview of current therapy
Treatment for croup includes oxygen, mist, epinephrine,
corticosteroids, and heliox.[30,31] Though mist has been
used for a long time, there is little evidence for or against
its benefit.[32] The evidence includes small randomised
and non-randomized trials, a study that used an animal
model of uncertain applicability, and, recently, a well-
masked randomised trial published by one of us (TPK).
[33-36] None of these studies found mist to be beneficial.
Epinephrine is clearly effective in the short-term, based on
several randomised trials using clinical scores, and non-
controlled trials using a range of 'objective' measures to
assess degree of respiratory distress.[34,37-40] In patients
with severe respiratory obstruction, its use probably pre-
vents or delays the need for endotracheal intuba-
tion.[40,41] Nebulized epinephrine is generally thought
to be safe.[30,31,42] Since the effect of epinephrine, how-
ever, is short-lived and does not alter the natural history
of the disease,[38] there appears to be no real benefit to its
use in children with mild symptoms.
Heliox (helium mixed with oxygen) allows efficient lami-
nar flow in narrower airways, and, at least in theory, can
delay or even prevent endotracheal intubation. [43] Two
small randomized trials in children with moderately
severe croup have been published. One compared heliox
to nebulized epinephrine and found the two interven-
tions to be equivalent.[44] The other study compared
heliox to standard oxygen therapy, and found a trend in
favor of heliox that was not statistically significant.[45]
The clinical benefit of steroids is well documented. In
addition to observations that steroids improve clinical
scores, randomized trials have shown a reduction in the
duration of endotracheal intubation,[46] the rate of intu-
bation, [4] the amount of treatment required with epine-
phrine,[3,5] the duration of hospitalization,[47] the rate
of hospitalization, [5,48] and the rate of return to the
ED.[49] Steroid therapy for croup is generally thought to
be safe. [31]
Unsubstantiated therapies: antibiotics, decongestants, & beta-
agonists
Other types of therapies sometimes administered to
patients with croup include antibiotics, decongestants,
and nebulized β-agonists. No evidence exists for their
benefit.
Variability in treatment practices
A recent study reported significant differences in the pro-
portion of children treated with mist, epinephrine, and
salbutamol based on whether physicians were pediatri-
cians or not.[50] All physicians in these two urban hospi-
tals, however, used corticosteroids in more than 90% of
children with croup. In contrast, our data from Alberta
shows that a much smaller proportion of children receive
corticosteroids, (e.g. only 22% at the 12 smaller hospi-
tals). In these same small hospitals, the same proportion
of children receive antibiotics or salbutamol; treatments
for which there is no evidence of efficacy.
Why are guidelines that address the management of croup a good 
choice for testing implementation strategies?
First, croup is an extremely common disease that is seen
in small rural health hospitals as well as in tertiary centres.
Second, a large body of published evidence clearly dem-
onstrates that properly timed treatment with corticoster-
oids can significantly reduce health care utilization,
without any significant adverse events. Furthermore,
understanding what constitutes best therapy is not diffi-
cult to grasp. Third, it is a reasonable assumption that hos-
pitalization is the primary determinant of health care
expenditures for the disease. Fourth, there is a substantial
variation in practice patterns and hospitalization rates
across Alberta. Therefore effective implementation strate-
gies should lower overall health care expenditures and
increase societal benefits.
Relevant systematic reviews
Strategies for implementing practice guidelines
Cochrane EPOC Group members have published two
'overviews' of systematic reviews of knowledge translation
interventions.[1,2] In general, these systematic reviews
found, that despite the relatively large number (~ 1,600)
of published articles which address the topic, only a com-
paratively small number (~ 100) have a semi-rigorous
design (randomised, quasi-randomised, controlled before
and after studies).[51] Many of these primary studies are
methodologically flawed in that they randomised subjects
by clusters, but used standard statistical techniques forImplementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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analyzing their results.[52] Only a comparatively small
number of trials have systematically examined the impact
of implementation strategies on both medical practice
and clinical outcomes, and very few studies have
addressed the cost effectiveness of clinical guidelines.[1]
The Cochrane EPOC Group has established a taxonomy
for classifying different types of implementation strate-
gies. Educational meetings (defined as participation of
health care providers in conferences, lectures, or work-
shops) show a range of effectiveness.[1] Interactive work-
shops have shown moderate to moderately large effects,
whereas didactic forums alone were ineffective.[1] Educa-
tional outreach visits, (defined as the use of a trained per-
son who meets with providers in their practice settings to
provide information with the intent of changing provid-
ers' performances), have shown small to moderate effects
on behaviour, though the authors point out that the cost
effectiveness is unclear. Reminders (defined as any inter-
vention, manual or computerised, that prompts the
health care provider to perform a clinical action) appear
to be more effective than audit and feedback but the
results have not been striking.[1] The identification of
local opinion leaders (defined as health professionals
nominated by their colleagues as 'educationally influen-
tial') has shown mixed results in studies published to
date, and the authors of this Cochrane systematic review
suggested that further research was required before this
technique becomes widespread.[1,2,53] Probably the
most consistent finding among systematic reviews is that
multi-faceted interventions (> 2 interventions of any type)
are more effective than single interventions.[1,2]
Management of children with croup
Two meta-analyses of randomized controlled trials exam-
ining the benefit of corticosteroids have been published.
Kairys et al. published a meta-analysis in 1989 of 10 pub-
lished randomized controlled trial's involving 1286
patients.[4] The analysis indicated that the use of steroids
in children hospitalized with croup is associated with a
significantly increased proportion of children showing
clinical improvement at 12 and 24 hours following treat-
ment, and a significantly reduced incidence of endotra-
cheal intubation. More recently, we (TPK and DWJ)
performed a meta-analysis of 24 randomized controlled
trial's, and found that corticosteroid treatment was associ-
ated with an improvement in croup score at 6, 12, and 24
hours, a decrease in epinephrine treatments, a decrease in
length of time spent in the emergency department, and a
reduction in hospital stay by 16 hours.[3]) A Cochrane
protocol has been submitted to examine humidified air
inhalation for treating croup, but has not been published
yet. No systematic reviews have been published or regis-
tered for either epinephrine or heliox.
Aim and objectives
The overall aim of this study is to identify, from a societal
perspective, the costs and associated benefits of three
strategies (of low, intermediate and high intensity respec-
tively) for disseminating and implementing a practice
guideline that addresses the management of croup.
Primary objective
To determine which of the three intervention strategies are
most effective at lowering the rate of hospital days per
1,000 disease episodes. The null hypothesis is that none
of the intervention strategies reduce hospital utilization
rates from baseline. The alternate hypothesis is that the
intervention strategies will have a graded degree of effect
on hospitalization rates, with the low intensity interven-
tion having minimal to no effect, the intermediate inten-
sity intervention having moderate but significant effect,
and the high intensity intervention having the greatest
effect.
Secondary objective
To determine which of the three intervention strategies are
most effective at increasing the use of therapies of known
benefit.
Other objectives
To determine which intervention strategy will most effec-
tively maintain or improve clinical outcomes and main-
tain or reduce the family pyschosocial burden. Clinical
outcomes assessed will include both uncommon severe
events, as well as average duration of clinical symptoms.
The assessment of family psychosocial burden will
include the number of hours of sleep missed by the child,
and the stress experienced by the primary caregiver (most
commonly the mother).
Economic analysis
To determine which of the three intervention strategies
will most effectively reduce total societal costs including
all health care costs, costs borne by the family, and costs
stemming from the strategies for disseminating guide-
lines. The null hypothesis is that neither the intermediate
nor the high intensity interventions will consume less
resources than the low intensity intervention. The alter-
nate hypothesis is that the intermediate intervention will
consume fewer resources than either the low intensity
intervention or the high intensity intervention.
Methods
Proposed trial design
We will conduct a cluster randomized controlled trial after
completing a baseline survey. In order to provide a com-
prehensive answer as to whether or not our interventions
are beneficial, we have obtained data from several differ-
ent sources. The stages are as follows.Implementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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1. Baseline survey (currently near completion):
▪ Utilizing administrative data, we have documented
Alberta health care utilization rates.
▪ We are documenting severe adverse outcomes in Alberta
utilizing administrative data, and both medical examiner
and records audit.
▪ Using this data, we have rank ordered Alberta hospitals
based on number of disease episodes and rates of hospi-
talization.
▪ We have enrolled the highest ranking 24 hospitals who
consented to participation.
▪ We are documenting practice patterns in these 24
selected Alberta hospitals utilizing medical records audit.
▪ Utilizing a prospective cohort questionnaire, we are doc-
umenting the duration of clinical symptoms of children
with croup and the psychosocial burden on their families
in the same 24 selected Alberta hospital emergency
departments
2. Development of clinical guidelines that address indica-
tions for drug therapy and hospital admission/discharge
criteria. The process will include:
▪ convening an guideline committee with a range of disci-
plines and professions;
▪ critically reviewing the published literature;
▪ drafting guidelines which meet standard criteria for
developing guidelines;
▪ review of the guidelines by both parents and a wide-
range of users (family physicians, nurses, and respiratory
therapists);
▪ obtaining approval of the guidelines from the Canadian
Pediatric Society, Canadian Association of Emergency
Physicians, and the Alberta Medical Association; and
▪ publishing the guidelines in journals such as the Cana-
dian Medical Association Journal.
3. Randomization of 24 Alberta hospitals to one of three
implementation strategies.
4. A follow-up survey whose purpose is to detect any
change from baseline by:
▪ documenting severe adverse outcomes and utilization
rates in Alberta;
▪ documenting practice patterns in the 24 Alberta hospi-
tals surveyed at baseline;
▪ documenting the duration of symptoms of children with
croup and the psychosocial burden on their families
attending these 24 hospital emergency departments.
Proposed sample size
The twenty-four participating hospitals were initially
selected by calculating anticipated hospital specific effect
sizes based on assuming that the effect of intervention
would be proportional to baseline admission rates taking
into account hospital-specific frequencies of disease epi-
sodes. Hospitals are to be randomized to one of three
intervention arms, eight hospitals per arm, after stratifica-
tion on baseline frequency of disease episodes. The power
of our study depends on the anticipated change in mean
hospital days as shown in Figure 1, which provides power
estimates plotted against percentage decrease based on
examining hospital stays over the three baseline and three
post-intervention years. (Appendix A – Details of calcula-
tions) A Bonferroni correction for the two comparisons of
intermediate and high intensity intervention against low
Illustration of Estimated Study Power Figure 1
Illustration of Estimated Study Power.
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intensity intervention has been included. The estimated
power (overall alpha = .05) to detect a 25% change is 0.80
for each comparison.
Recruitment
Recruitment of hospitals
All 24 hospitals have been approached and have con-
sented to participate in our study.
Recruitment of families to complete prospective survey
As of Oct. 27th, 2002 we have recruited a total of 170 chil-
dren into our baseline cohort and 95% have been con-
tacted daily until resolution of symptoms. We will
continue to recruit patients until April 30th, 2003. Given
our rate of enrolment to date, we anticipate enrolling
between 450 and 500 patients in the baseline cohort. The
intervention and follow-up sample will be obtained over
a total of 24 months, as opposed to the baseline in which
we will have enrolled patients for only 13 months. There-
fore, conservatively, enrolment should be ~ 900 patients
in the follow-up cohort.
Practical arrangements for allocating participants to trial 
groups
Proposed strata, rationale and method of allocation
As noted above, a total of 24 hospitals have agreed to par-
ticipate in our study. We will stratify these hospitals into
three levels based on the average number of croup cases
diagnosed by affiliated physicians per year (< 100 cases/
year = small volume hospitals; 100 to 700 cases per year =
medium volume hospitals, and > 700 cases per year = large vol-
ume hospitals). Non-stratified randomization of only 24
hospitals into three intervention arms could easily result
in substantially more hospitals of one stratum in one
intervention arm than the other arms. Therefore, given the
significant differences in total number of disease episodes,
number of hospitalizations, hospitalization rates, and
likely other significant differences between the different
sized hospitals, non-stratified randomization could sig-
nificantly bias our results. A statistician not otherwise
involved in our study will randomise hospitals within
each of the three strata to one of the three intervention
arms by computer software.
Planned trial interventions
Development of croup clinical practice guidelines
Development committee
The Alberta Medical Association Clinical Practice Guide-
line Program (Alberta Medical Association Clinical Practice
Guidelines Program) appointed DWJ as Chair, and the
health care professionals representing pediatric emer-
gency medicine (TPK, WC); pediatric pulmonary; pediat-
ric infectious diseases; emergency medicine; rural family
medicine; respiratory therapy; and nursing to a committee
that was charged with developing the guidelines.
Criteria for developing a practice guideline
We have used both the criteria developed by Grimshaw
and Shaneyfelt as the basis for formulating our guide-
lines.[1,2]
Systematic review of the literature
Utilizing the Alberta Research Centre for Child Health
Evidence (ARCHE), we carried out a systematic literature
review to ensure we had identified all primary published
studies addressing the management of children with
croup. We have completed a draft of the guidelines.
Remaining steps prior to completion of croup clinical practice 
guideline
When the guidelines are in final form, a parents' group
will critically review the guidelines for clarity and content.
As well, the guidelines will be reviewed by a randomly
selected group of family physicians for clarity and clinical
relevance. Once development of the guidelines is com-
plete, we will seek endorsement by the Canadian Pediatric
Society and the Canadian Association of Emergency Phy-
sicians. We will also submit the guidelines to the Cana-
dian Medical Association Journal for publication.
The three intervention strategies
The intervention strategies to be compared will be a) mail-
ing of printed educational materials (PEMs) (low inten-
sity intervention); b) mailing PEMs plus a combination of
interactive educational meetings, educational outreach
visits, and reminders (intermediate intensity interven-
tion); and c) mailing PEMs, interactive sessions, outreach
visits, reminders plus identification of local opinion lead-
ers (high intensity intervention.
Low intensity intervention
The low intensity intervention is the current strategy uti-
lized by the Alberta Medical Association Clinical Practice
Guidelines Program for disseminating new guidelines. This
intervention arm will serve as a "control". The Croup
Guidelines will be mailed to each physician registered
with the Alberta College of Physicians and Surgeons. The
Guidelines will also be available on the Alberta Medical
Association Clinical Practice Guidelines Website.
Intermediate intensity intervention
The intermediate intensity intervention utilizes tech-
niques that have consistently shown at least a moderate
impact on professional behavior. We will work through
existing organizational structures in order to more closely
simulate how the Alberta Medical Association Clinical Prac-
tice Guidelines Program might disseminate future guide-
lines. More specifically, the Alberta Medical Association
Clinical Practice Guidelines program and the Croup clinical
practice guideline committee will work with the Universi-
ties of Calgary and Alberta Continuing Education Pro-Implementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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grams to develop an interactive educational program for
physicians, nurses, and respiratory therapists. Utilizing
the existing Continuous Quality Improvement Staff in
each Health Region, each hospital's admitting physicians,
acute care nurses and respiratory therapists will be invited
to participate in the interactive educational program car-
ried out by one of the Croup Clinical Practice Guideline
Committee members. A "local champion" will also be
identified. They will conduct educational outreach visits
to physicians, nurses, and respiratory therapists who did
not attend the interactive educational program.
High intensity intervention
The high intensity, intervention utilizes a multi-faceted
approach described by Lomas.[3] This approach uses a
variety of techniques, including interactive educational
meetings, educational outreach visits, reminders, identifi-
cation of local opinion leaders and establishment of a
local consensus process. The physician-focused multi-fac-
eted dissemination strategy will involve identification of
physician "opinion leaders" at each hospital randomized
to this arm. All physicians with admitting privileges to a
hospital will be asked to complete a validated question-
naire for the purpose of identifying the "local opinion
leader".[4] All "opinion leaders" will be invited to partic-
ipate in a workshop on the evidence for the practice guide-
line's recommendations and on basic principles of
behaviour change.
Planned inclusion/exclusion criteria
Health care utilization using administrative databases
Alberta Health and Wellness, a branch of the Alberta pro-
vincial government, is the custodian of several data
sources that are accessible for research purposes. These
databases can be linked, and are considered to be of good
quality with reliable personal identifiers on more than
95% of records. Through collaboration with the Project
Coordinator, Health Surveillance Branch, Alberta Health
& Wellness, we extracted the data specified below from the
Canadian Institute for Health Information Hospital Inpa-
tient database, Alberta Ambulatory Care Classification
System, the Alberta Health Care Insurance Plan (AHCIP)
Payment Database, and the AHCIP Registry Dataset.
All children 0–6 years of age and 6–16 years of age who
are Albertan residents, and who have been evaluated and
diagnosed by an Albertan physician to have croup (ICD-
9-CM 464.1 Acute Tracheitis, 464.2 Acute Laryngotracheitis,
and 464.4 Croup, either as a primary or secondary diagnosis)
have been included in our utilization data.
Methodological assignment of physicians to hospital
Encrypted physician identifiers are available for each
health care encounter in which a child was diagnosed to
have croup. Each of the physicians appearing in our data-
set were assigned to a specific hospital based on following:
first, the hospital to which they admitted children with
croup (62% of physicians); second, the hospital clinic or
emergency department at which they diagnosed children
to have croup (82% of physicians); or, third, the hospital
to which a physician associate admitted or evaluated chil-
dren with croup (93% of all physicians). (Physicians who
shared the same billing address where assumed to be asso-
ciates.)
Adverse outcomes
We have used administrative databases, selected medical
record audit, and review of medical examiner cases to
establish Alberta morbidity and mortality rates for the six-
year baseline. Data gathered from these three sources will
allow us to establish the incidence of rare but severe out-
comes such as death, anoxic brain injury, and endotra-
cheal intubation.
Administrative databases were screened for any children
with a diagnosis of croup who died, were intubated (ICD-
9-CM 96.04), or were also diagnosed during the same
admission to have anoxic brain damage (ICD-9-CM
348.1) or cerebral edema (ICD-9-CM 348.5).
Retrospective record audit
We are auditing the medical records of children identified
from the administrative databases who met the above cri-
teria. The baseline review is almost complete, and we will
repeat the process in follow-up. To double check that our
reliance on administrative databases has not resulted in
missed patients, we have also reviewed the manual admis-
sion logs for Alberta Children's Hospital and the Univer-
sity of Alberta Hospital intensive care units, and will
contact the medical records departments at each of the
regional medical centers (Medicine Hat, Lethbridge, Red
Deer, Fort McMurray, Grande Prairie).
Medical examiner's office
We have also contacted the Alberta Medical Examiners'
Offices and have arranged for review of children ≤ 16
years of age that died of "respiratory causes".
Practice patterns using retrospective medical record audit
Retrospective record audit will be used to establish the
extent to which physicians use effective therapies for
croup. The baseline review is almost completed, and will
be repeated for the follow-up period. Each of the 24 tar-
geted hospitals were asked to generate a list of medical
record numbers using standard ICD9 codes as above that
identify all children that were hospitalized and/or evalu-
ated in the emergency department with croup. Medical
records pertaining to all hospitalized children were (will
be) reviewed. Of those children evaluated in the emer-
gency department, a maximum of 30 patients per yearImplementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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were randomly selected and reviewed. For the follow-up
record audit, since significant annual change is likely to
occur, we will audit up to a maximum of 100 records to
allow greater accuracy for our annual estimates.
Clinical outcomes & psychosocial burden using prospective 
questionnaire
The parents of all children evaluated in, or admitted to
each of the 24 hospitals with a diagnosis of croup between
September and May during the baseline, intervention, and
follow up periods will be approached to participate in a
follow up telephone survey by a staff nurse. A log of all
children diagnosed to have croup will be maintained to
allow the comparison of those children enrolled to those
not enrolled.
Identification & enrolment of participating hospitals
As noted above, Alberta hospitals were rank ordered based
on the number of disease episodes and rates of hospitali-
zation for a six-year period. We then approached in this
order each of the hospital administrators and clinical staff
for permission to include their hospital in our study until
a total of 24 hospitals consented (the staff of 11 hospitals
refused to participate for reasons ranging from "antici-
pated closing of the hospital in the near future" to "too
heavy an administrative workload to participate in a
study").
Proposed duration of treatment period
Detailed planning for the intervention strategies will take
place between February and July 2003. We will initiate
each of the interventions in August, 2003 and conclude
them in March, 2004.
Duration of the baseline and follow-up periods
Utilization and adverse outcome data obtained from the 
administrative datasets
We have extracted data from administrative databases
from April 1st, 1994 to March 31st, 2000, providing six
years of data. In summer 2006, we will again extract data
from administrative databases from April 1st, 2000 to
March 31st, 2006. Extraction of data across these time peri-
ods will allow us to extend the baseline utilization rates
from six to nine years. Most importantly, this will ensure
no significant changes occur just prior to the study inter-
ventions. Extraction of data through March 31st, 2006 will
provide utilization data for the intervention and two fol-
low-up years.
Practice pattern data obtained from medical record audit
We are just completing an audit of medical records of chil-
dren diagnosed to have croup based on ICD9 coding from
April 1st, 1994 to March 31st, 2000. By late 2006, we will
repeat an identical audit of medical records of children
diagnosed as having croup between April 1st, 2000 to
March 31st, 2006. This timetable for extraction of data
provides the above delineated advantages.
Clinical outcome & psychosocial burden data obtained from 
prospective questionnaire
Duration of enrolment
The parents of children admitted to each of the 24 hospi-
tals with a diagnosis of croup during "croup season" (Sept
1st to May 31st) from November 1st, 2001 and finishing
March 31st, 2006, will be asked by a staff nurse to partici-
pate in a telephone survey.
Duration & mechanism of telephone follow up
The enrolment and consent forms are then faxed to the
study coordinator (JW). She assigns the case to one of
three centrally located and trained study investigators
who will contact the primary caretaker within 24 hours of
enrolment. The initial telephone interview takes 20 min-
utes. Daily telephone interviews with the primary care-
taker occur until the child has been symptom-free for 24
hours.
Proposed primary and secondary outcome measures
The primary outcome will be the rate of hospital days per
1,000 disease episodes. If differences in rate of hospital
days between intervention groups are detected, we will
explore to what degree they are due to a change in rates of
admission versus a change in hospital lengths of stay.
The secondary outcomes will be utilization of appropriate
therapies including:
▪ Proportion of patients treated in the emergency depart-
ment and hospital with a corticosteroid.
▪ Proportion of patients evaluated in emergency depart-
ment for at least three hours after treatment with corticos-
teroids before the decision to admit to hospital is made.
▪ Time to treatment with corticosteroids in both emer-
gency department and hospital patients.
Other outcomes
Clinical outcomes
To determine which dissemination strategy will most
effectively maintain or improve clinical outcomes:
▪ by reducing or maintaining the number of uncommon,
severe clinical events such as intubation, respiratory and
cardiac arrest, anoxic brain injury, or death.
▪ by reducing, (in a prospective cohort of children
enrolled from each hospital) croup symptoms on days 1,
2, and 3 following assessment, as measured by a tele-
phone follow-upImplementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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▪ assessment tool (Telephone Out Patient (TOP) score).
Psychosocial burden
To determine which dissemination strategy will most
effectively maintain or reduce the psychosocial burden on
parents by
▪ reducing, (in a cohort of children enrolled from each
hospital), the stress experienced by the primary caregiver
due to the child's illness on days 1–3 following assess-
ment.
▪ reducing, (in a prospective cohort of children enrolled
from each hospital), the number of hours of sleep missed
by the child due to croup on days 1–3 following assess-
ment.
How will the outcome measures be measured at follow up?
Utilization outcomes
Previously discussed.
Adverse outcomes
Previously discussed in part.
Development of data abstraction sheet
The Principal Investigator and Study Coordinator, follow-
ing an informal review of medical records, developed a
customized Access relational database. This draft database
was pilot tested and revised before beginning formal
review.
Auditing process
Because these cases are significantly more complex, only
the study coordinator and another trained senior pediatric
emergency nurse will perform these audits. The principal
investigator and the two nurses will meet regularly during
the baseline and follow up audits, to discuss cases and any
difficulties encountered in auditing. To establish the
degree of agreement between auditors, the three will
review a random selection of medical records.
Case identification: multiple and overlapping methods
In order to minimize the likelihood that any adverse out-
comes will be missed, overlapping methods for identify-
ing cases will be used. Specifically, we will obtain
provincial medical examiner records, and hospital admin-
istrative data from the province, all the health regions, and
all the hospitals in urban areas.
Practice pattern outcomes
Development of data abstraction sheet
After an informal review of medical records, a customized
Access relational database was developed. This draft data
sheet was piloted and revised, before beginning formal
review.
Training & monitoring of medical record auditors
The projector coordinator has trained two research assist-
ants to review medical records and directly enter data in a
relational database (Access). The project coordinator and
each of the research assistants will review a randomly
selected number of records through the study to check
accuracy in data abstraction.
Accuracy of ICD9 coding
To assess the accuracy of using ICD9 coding to identify
children diagnosed with croup, we will examine whether
health record analysts coded records in the same way at
each of the 24 hospitals. We will determine what percent-
age of children were coded as croup using the standard
codes met a formal definition for croup (acute onset of
stridor associated with a "seal-like" barking cough). Also
to explore whether some hospitals use other ICD9 codes
for children with croup, we will generate a list of potential
alternative codes. Using this list of potential alternative
ICD9 codes, we will review a random selection of medical
records using these codes.
Clinical & psychosocial burden outcomes
RMO database
We are maintaining a database of all children diagnosed
as having croup whose parents refused, were missed, or
are otherwise excluded. Demographics and disease char-
acteristics of children and their families in this database
will be compared to those families who are administered
the survey to ascertain if the two populations are different.
Telephone interviewing techniques
Several procedures should enhance the reliability of tele-
phone data collection. a) One study investigator will com-
plete all telephone follow up for a given family. b) At the
time of enrolment the primary caretaker of the child will
be identified, and every effort will be made to conduct all
follow-up calls with this person. c) The questions will
have standardized responses. d)A standard audio record-
ing of a child with croup will be played to the caregiver to
aid them in identifying the easily recognizable and dis-
tinctive cough.
Proposed analyses
The principal analysis will examine hospital stays arising
from individual disease episodes over the six-year base-
line and study period. We will apply a linear mixed model
(Laird-Ware approach) incorporating random effects for
hospital, year within hospital, as well as fixed effects for
intervention and year. We will also pursue a more detailed
explanatory analysis incorporating individual subject
characteristics (age, sex) as well as random effects for
admission and discharge physician. Additionally we will
develop similar models for length of stay restricting to dis-
ease episodes leading to admissions, and mixed effectsImplementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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logistic regression model for admissions. Secondary anal-
yses relating to steroid use and Telephone OutPatient (TOP)
scores will follow a similar format. The examination of
day 1- 3 TOP scores will require augmenting the basic
model framework to include random subject effects and a
serially correlated (within subject) residual error structure.
No subgroup analyses are planned.
Economic analysis
An economic analysis will be carried out from a societal
perspective with costs classified as either payer (costs born
by the province) or non-payer (costs born by individuals
or the families of children with croup). The analysis will
include all health care costs, costs borne by the family,
and costs stemming from the strategies for implementing
guidelines.
Potential benefits
Potential benefits will be considered to be the duration of
croup symptoms and the absence of any severe adverse
outcomes among children.
Overview of costing methods
Costing information will be gathered in sufficient detail to
allow a comparison of costs and benefits. The form that
the analysis will take will depend on the relative ratios of
cost versus benefit. For example, if either of the two exper-
imental strategies (non-standard) achieve similar or better
clinical outcomes at decreased or equal costs as the stand-
ard dissemination strategy, the experimental interven-
tions will be judged as cost-effective. Alternatively, if the
experimental interventions yield increased benefits at
increased costs, a ratio of the incremental cost per out-
come gained will be calculated. And last, if the experimen-
tal interventions yield decreased benefits but are
associated with increased or equal costs, the standard dis-
semination strategy will be judged to be the most cost-
effective. (Please note we have specifically avoided using
any reference to either cost-effective analysis or cost-bene-
fit analysis. [5,6])
Health care costs
Payer costs resulting from the provision of health care will
be estimated by first determining from the administrative
database the total number of physician visits, emergency
department visits, days of hospitalization, patient trans-
ports, and days in an intensive care unit (Edmonton or
Calgary only). Costs per physician visit will be based on
the Alberta physician fee schedule. Costs per emergency
department visit, and hospital day will be based on pub-
lished standards for Alberta.[7] Costs for drugs, radio-
graphs, and laboratory tests will be based on provincial
standards. For the Edmonton and Calgary hospitals
included in the randomised trial and for any intensive
care patients, specific hospital case costing is available
thereby allowing a unique cost estimate for each patient.
Air transport costs will be estimated to be $8 per air mile.
Implementation strategy costs
Costs of the three-implementation strategies will be clas-
sified as either as payer and non-payer based on whether
or not the province assumes responsibility for the cost.
They will be estimated from the costs of publication and
mailing of questionnaires or learning materials, and the
time spent in meetings, organising, travel, and preparing
for presentations by the Alberta Medical Association sup-
port staff, Regional Quality Assurance staff, "local cham-
pions", opinion leaders, and any associates. (The hourly
wage will be assumed to be $100 per hour for physician
time and to be the mean provincial wage for other health
care professionals and administrators.)
Costs to the family
The costs borne by families will be considered to be non-
payer. The amount of work missed (including both wages
and house work), travel time, parking and ambulance
costs by each family will be assumed to equal the mean
values determined by the prospective survey of children
with croup. The value of the lost wages will be estimated
by applying a mean wage rate to missed work time,
obtained from STATS Canada for Alberta. The values for
travel time, parking costs, and ambulance costs will be
taken from published standards for Alberta.[7]
Calculation of societal costs
Total societal costs (the sum of payer and non-payer costs)
for each hospital will be calculated for the 9 baseline
years, the one-year of intervention, and the two years of
follow-up. Given the year-to-year variability in the inci-
dence of croup, the total societal costs for each year will be
adjusted for disease incidence (total costs per year divided
by the number of episodes of croup diagnosed that year
by those physicians assigned to the hospital). An average
cost per year for the baseline period will be calculated. Sta-
tistical assessment of whether or not costs differ between
the three intervention groups will be calculated by the
Laird-Ware model with baseline costs as the covariate.
(This type of analysis will allow us to simultaneously
compare costs at three time points (the intervention year
and two years of follow-up), while adjusting for the base-
line cost)
Quality of Life (QOL) measurements
We will not utilize any QOL measures in our study. None,
to our knowledge, have been developed for use in chil-
dren with acute, transient illnesses.Implementation Science 2006, 1:10 http://www.implementationscience.com/content/1/1/10
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Data safety and monitoring committee
Given that the study intervention does not pose any direct
risk to patients or health care professionals, a Data Safety
and Monitoring Committee is not necessary.
Proposed methods for protecting against sources of bias
Masking of allocation
As noted above, a statistician not aware of our study ques-
tion will allocate hospitals using a standard computer ran-
domization software.
Cluster randomization
Given that our study interventions specifically target phy-
sicians and other health care workers, one threat to the
validity of our study is the possibility of communication
between health care workers randomized to different
intervention arms. To minimize the likelihood of this pos-
sibility, we have chosen hospitals as our unit of randomi-
zation and analysis. All hospitals but three are located in
different cities and towns, each with a significant distance
between them. However, three of the six hospitals with
large volumes are located in Edmonton, so at least two of
the Edmonton hospitals will be randomized to different
intervention arms.
Inability to completely blind health care workers to study intent
Another potential threat to the validity of our study is that
– as a result of needing to approach hospital clinical staff
to obtain consent for their hospital to be included in our
study – hospital staff had to be informed of the intent of
the study. We have tried to minimize further unnecessary
contamination, however, by instructing our study staff to
avoid discussing the study's main purpose with hospital
staff, and speaking only about the operational details of
their particular intervention.
Assessment of outcomes
The assessment of outcome measures will be masked as
much as possible without awareness of study purpose or
intervention assignment. The data analyst responsible for
extracting and linking the administrative databases will
not be informed as to specific purpose of the study nor to
which intervention arm each hospital has been rand-
omized. Medical record auditors will not be informed as
to the specific purpose of the study nor to which interven-
tion arm each hospital has been randomized. Parents of
children with croup will not be told of the overall purpose
of the study nor the intervention arm to which their hos-
pital is randomized.
Analysis
The health economist (CM) will review and clean the eco-
nomic data without being aware of the specific hospital or
intervention (for this process, hospital and intervention
identifiers will be removed). Furthermore the statistician
(RB) will be provided with data segregated into the three
intervention arms labelled with an encrypted hospital and
intervention identifier.
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